Latest News

BioNtech SE expands collab with Genmab A/S

Hexabody binding to the surface of a T cell. © Genmab A/S


by tg

As Genmab’s Hexabody tumour antibody platform is advancing, BioNTech has secured a licence in the field of immunotherapy to co-develop antibodies on 50:50 base.

By means of the exended collaboration, BioNTech SE aims to broaden its pipeline of monospecific antibodies against malignant solid tumours. Genmab’s first candidate GEN1053/BNT313 is expected to enter clinical trials in Q4/2022. BioNTech and Genmab have agreed to share development costs and potential future revenues on a 50:50 basis.
 
The companies have been already working together since 2015 to develop bispecific cancer antibodies - so- called Duomabs –to improve current immunotherapy options for cancer patients. They have two candidates resulting from the collaboration in clinical trials: GEN1046/BNT311 is being evaluated in two Phase I/II clinical trials for the treatment of advanced solid tumours (NCT04937153, NCT03917381) and in a Phase II trial in patients with non-small cell lung cancer (NSCLC) (NCT05117242). In addition, GEN1042/BNT312 is being investigated in a Phase I/II study (NCT04083599) for the treatment of metastatic or locally advanced solid tumours.

Genmab’s licenced hexabody GEN1053/BNT313 is an agonistic CD27 antibody specifically designed to form an antibody hexamer upon binding of its target structure on the cell membrane of T cells.
 

Growing investor interest in biotechnology

Institutional investors and financial analysts reported at the German Equity Forum that the biotech sector has become significantly more attractive....

Ethris inks €15m deal with Indian Ciplas

The investment is aimed at establishing a long-term strategic partnership until the end of Q1/2023 between Cipla and Ethris for the development of...

Evonetix extends Series B financing to US$54m

According to Evonetix Ltd, a benchtop gene synthesis specialist, the investment, which also includes existing investors such as Molten Ventures,...

Benefits of booster campaigns questionable

While Pfizer Inc and BioNTech SE financial outlooks in February prognosed more than $50bn in combined coronavirus disease (COVID-19) vaccine sales in...

Chong Kun Dang Pharm licences Synaffix ADC platform

Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged...

Jolt Capital boosts BC Platforms with $20m

Espoo-based BC Platforms, an international healthcare data provider and software developer, in November has baged an investment of $20m from the...

First allogeneic cancer immunotherapy hits market

On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...